AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Spyre Therapeutics, Inc.
Video analysis: SYRE
All videosNo video analysis for this stock yet. Request one from our team.
News: SYRE
Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 2,106 shares of common stock of Spyre and 745 restricted stock units (“RSUs”) to one non-executive employee as an equity inducement award under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on September 1, 2026 and were material to the employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences: Event : Citi 2026 BioPharma Back to School Conference – New York Date: Wednesday, September 9, 2026 Fireside Time: 10:00 am ET Event: Wells Fargo 21st Annual Healthcare Conference – Boston Date: Thursday, September 10, 2026 Fireside Time: 8:00 am ET Event: Stifel 2026 Virtual Immunology and Inflammation Forum Date: Wednesday, September 23, 2026 Fireside Time: 8:30 am ET Members of the Spyre management team will also host one-on-one investor meetings during the conferences.
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock?
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles
Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock is trading lower on Wednesday after the company shared topline findings from the rheumatoid arthritis (RA) segment of its Phase 2 SKYWAY trial for SPY072.
